Drugs & Targets FDA grants breakthrough designation for Rina-S in advanced endometrial cancer September 05, 2025Vol.51 No.32
Podcast Gardiner Harris, acclaimed health care and pharma journalist, on his New York Times bestselling book August 27, 2025
Book ReviewFree When public service ends abruptly, do books provide solace? An escape? Perspective?Former NIH and FDA employees tell us what they are reading in 2025 August 08, 2025Vol.51 No.31By Sara Willa Ernst
Drugs & TargetsFree FDA gives accelerated approval to Modeyso as the first and only treatment for recurrent H3 K27M-mutant diffuse midline glioma August 08, 2025Vol.51 No.31
News Analysis Vinay Prasad falls from grace at FDA upon flunking Trump political purity testMAHA leaders agree on one point: COVID was mishandled. Is that enough to run science-based agencies? August 01, 2025Vol.51 No.30By Claire Marie Porter
Drugs & Targets FDA grants priority review for Imfinzi in gastric and GEJ cancer August 01, 2025Vol.51 No.30
Oncologist biotech entrepreneur George Tidmarsh joins FDA as CDER directorHis appointment came out of “proximity” to Makary and Bhattacharya July 25, 2025Vol.51 No.29By Claire Marie Porter
Cancer Policy Right-wing provocateur Laura Loomer comes for FDA’s Vinay Prasad July 25, 2025Vol.51 No.29By Claire Marie Porter
Cancer Policy The effects of NIH, FDA cuts will be felt for decades, CBO report estimates July 25, 2025Vol.51 No.29By Paul Goldberg
Cancer Policy COI statement prohibits “unseemly advocacy,” “undue influence” by industry rep on ODAC July 25, 2025Vol.51 No.29By Paul Goldberg
